{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:31:28Z","timestamp":1772166688560,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K13463"],"award-info":[{"award-number":["25K13463"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The global crisis of antimicrobial resistance (AMR) necessitates robust antimicrobial stewardship. The World Health Organization\u2019s (WHO) Access, Watch, Reserve (AWaRe) classification is a key tool for guiding antibiotic prescribing to combat AMR. The WHO\u2019s global target was to have at least 60% of antibiotic consumption fall into the Access category by 2023. This study evaluated the effectiveness of localized interventions toward this goal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, longitudinal study analyzed oral outpatient antibiotic prescriptions at Kochi Medical School Hospital from April 2022 to June 2025. Data included defined daily doses (DDDs), days of therapy (DOTs), and AWaRe classifications. Based on a preceding analysis, the antimicrobial stewardship team (AST) implemented targeted, department-specific educational interventions starting in April 2024. The impact was evaluated using seasonally adjusted time-series analysis and regression models. The study also included a survey of\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      susceptibility to levofloxacin, ciprofloxacin, and sulfamethoxazole\/trimethoprim from outpatient urinary isolates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The AST intervention led to a statistically significant increase in the usage proportion and DDDs of Access antibiotics (+\u20092.92%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005 and +\u2009376.5 DDDs,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001, respectively), with a corresponding decrease in Watch antibiotics (-3.00%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). However, DOTs did not significantly change, indicating the intervention primarily impacted drug choice, not treatment duration. Top prescribed agents were clarithromycin (24.2%), sulfamethoxazole\/trimethoprim (20.7%), and rifaximin (10.7%).\n                      <jats:italic>E. coli<\/jats:italic>\n                      susceptibility to levofloxacin and ciprofloxacin was low (&lt;\u200980% overall), particularly in extended-spectrum \u03b2-lactamase (ESBL)-producing strains (~\u200910%). Sulfamethoxazole\/trimethoprim susceptibility remained high overall (\u2265\u200980%) but was low (&lt;\u200980%) for ESBL-producing strains.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AST interventions successfully shifted outpatient prescribing from Watch to Access antibiotics, demonstrating that targeted interventions can modify prescribing behavior. However, challenges remain, such as addressing treatment duration and achieving broader goals. The observed resistance patterns highlight the critical need for prescribers to consult local antibiograms. Future strategies require a more comprehensive approach, including real-time alerts and improved diagnostics, to further optimize antibiotic use and combat AMR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00525-3","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T15:23:59Z","timestamp":1766676239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of a tailored, department-specific antimicrobial stewardship team intervention based on AWaRe guidelines: a single-center, cohort, interrupted-time series study"],"prefix":"10.1186","volume":"12","author":[{"given":"Yusuke","family":"Yagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"525_CR1","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.2147\/IDR.S290835","volume":"13","author":"MAA Majumder","year":"2020","unstructured":"Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infect Drug Resist. 2020;13:4713\u201338.","journal-title":"Infect Drug Resist"},{"key":"525_CR2","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1017\/ash.2023.164","volume":"3","author":"S Mudenda","year":"2023","unstructured":"Mudenda S, Daka V, Matafwali SK. World health organization aware framework for antibiotic stewardship: where are we now and where do we need to go? An expert viewpoint. Antimicrob Steward Healthc Epidemiol. 2023;3:e84.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"525_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.cmi.2022.08.009","volume":"28","author":"M Sharland","year":"2022","unstructured":"Sharland M, Zanichelli V, Ombajo LA, Bazira J, Cappello B, Chitatanga R, Chuki P, Gandra S, Getahun H, Harbarth S, Loeb M, Mendelson M, Moja L, Pulcini C, Sati H, Tacconelli E, Zeng M, Huttner B. The WHO essential medicines list aware book: from a list to a quality improvement system. Clin Microbiol Infect. 2022;28:1533\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"525_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2024.02.003","volume":"30","author":"L Moja","year":"2024","unstructured":"Moja L, Zanichelli V, Mertz D, Gandra S, Cappello B, Cooke GS, Chuki P, Harbarth S, Pulcini C, Mendelson M, Tacconelli E, Ombajo LA, Chitatanga R, Zeng M, Imi M, Elias C, Ashorn P, Marata A, Paulin S, Muller A, Aidara-Kane A, Wi TE, Were WM, Tayler E, Figueras A, Da Silva CP, Van Weezenbeek C, Magrini N, Sharland M, Huttner B, Loeb M. WHO\u2019s essential medicines and aware: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin Microbiol Infect. 2024;30:S1\u201351.","journal-title":"Clin Microbiol Infect"},{"key":"525_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.2471\/BLT.20.270934","volume":"99","author":"B Simmons","year":"2021","unstructured":"Simmons B, Ariyoshi K, Ohmagari N, Pulcini C, Huttner B, Gandra S, Satta G, Moja L, Sharland M, Magrini N, Miraldo M, Cooke G. Progress towards antibiotic use targets in eight high-income countries. Bull World Health Organ. 2021;99:550\u201361.","journal-title":"Bull World Health Organ"},{"key":"525_CR6","unstructured":"The AMR One Health Surveillance Committee. Nippon AMR One Health Report (NAOR) 2023. Ministry of Health, Labour and Welfare. 2024. https:\/\/www.mhlw.go.jp\/content\/10900000\/001268945.pdf. Accessed 13 Aug 2025."},{"key":"525_CR7","doi-asserted-by":"publisher","first-page":"dlac048","DOI":"10.1093\/jacamr\/dlac048","volume":"4","author":"YM Bezabih","year":"2022","unstructured":"Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, Dessalegn N, Enyew A, Roujeinikova A, Alamneh E, Mirkazemi C, Peterson GM, Bezabhe WM. Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist. 2022;4:dlac048.","journal-title":"JAC Antimicrob Resist"},{"key":"525_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/antibiotics12060951","volume":"12","author":"S Abu-Ajaleh","year":"2023","unstructured":"Abu-Ajaleh S, Darwish Elhajji F, Al-Bsoul S, Abu Farha R, Al-Hammouri F, Amer A, Al Rusasi A, Al-Azzam S, Araydah M, Aldeyab MA. An evaluation of the impact of increasing the awareness of the WHO Access, Watch, and reserve (AWaRe) antibiotics classification on knowledge, attitudes, and hospital antibiotic prescribing practices. Antibiot (Basel). 2023;12:951.","journal-title":"Antibiot (Basel)"},{"key":"525_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jhin.2023.12.001","volume":"144","author":"A Zaffagnini","year":"2024","unstructured":"Zaffagnini A, Rigotti E, Opri F, Opri R, Simiele G, Tebon M, Sibani M, Group ENSUREW, Piacentini G, Tacconelli E, Carrara E. Enforcing surveillance of antimicrobial resistance and antibiotic use to drive stewardship: experience in a paediatric setting. J Hosp Infect. 2024;144:14\u20139.","journal-title":"J Hosp Infect"},{"key":"525_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/BF01584358","volume":"17","author":"S Natsch","year":"1998","unstructured":"Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC\/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17:20\u20134.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"525_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(17)30724-7","volume":"18","author":"M Sharland","year":"2018","unstructured":"Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, Magrini N, 21st WHO Expert Committee on Selection and Use of Essential Medicines. Classifying antibiotics in the WHO essential medicines list for optimal use-be aware. Lancet Infect Dis. 2018;18:18\u201320.","journal-title":"Lancet Infect Dis"},{"key":"525_CR12","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC\/DDD Index. 2025. Norwegian Institute of Public Health. 2024. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 13 Aug 2025."},{"key":"525_CR13","unstructured":"Centers for Disease Control and Prevention. Antibiotic Use and Resistance (AUR) Module. CDC. 2019. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/11pscaurcurrent.pdf. Accessed 13 Aug 2025."},{"key":"525_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/QCO.0000000000000228","volume":"29","author":"Z Tandogdu","year":"2016","unstructured":"Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29:73\u20139.","journal-title":"Curr Opin Infect Dis"},{"key":"525_CR15","unstructured":"World Health Organization (WHO). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. World Health Organization. 2022. https:\/\/www.who.int\/initiatives\/glass. Accessed 13 Aug 2025."},{"key":"525_CR16","doi-asserted-by":"publisher","first-page":"e0021321","DOI":"10.1128\/JCM.00213-21","volume":"59","author":"R Humphries","year":"2021","unstructured":"Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards Institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol. 2021;59:e0021321.","journal-title":"J Clin Microbiol"},{"key":"525_CR17","doi-asserted-by":"crossref","unstructured":"Weinstein MP, Lewis JS 2. The clinical and laboratory standards Institute subcommittee on antimicrobial susceptibility testing: Background, organization, functions, and processes. J Clin Microbiol. 2020;58:e01864\u201319.","DOI":"10.1128\/JCM.01864-19"},{"key":"525_CR18","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 31st ed, M100. (). Clinical and Laboratory Standards Institute. 2021. https:\/\/www.treata.academy\/wp-content\/uploads\/2021\/03\/CLSI-31-2021.pdf. Accessed 13 Aug 2025."},{"key":"525_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12874-021-01306-w","volume":"21","author":"SL Turner","year":"2021","unstructured":"Turner SL, Karahalios A, Forbes AB, Taljaard M, Grimshaw JM, McKenzie JE. Comparison of six statistical methods for interrupted time series studies: empirical evaluation of 190 published series. BMC Med Res Methodol. 2021;21:134.","journal-title":"BMC Med Res Methodol"},{"key":"525_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/sim.9669","volume":"42","author":"C Bottomley","year":"2023","unstructured":"Bottomley C, Ooko M, Gasparrini A, Keogh RH. In praise of Prais-Winsten: an evaluation of methods used to account for autocorrelation in interrupted time series. Stat Med. 2023;42:1277\u201388.","journal-title":"Stat Med"},{"key":"525_CR21","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/jac\/dku005","volume":"69","author":"J van den Broek d\u2019Obrenan","year":"2014","unstructured":"van den Broek d\u2019Obrenan J, Verheij TJ, Numans ME, van der Velden AW. Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment. J Antimicrob Chemother. 2014;69:1701\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"525_CR22","doi-asserted-by":"crossref","unstructured":"Chandy SJ, Naik GS, Charles R, Jeyaseelan V, Naumova EN, Thomas K, Lundborg CS. The impact of policy guidelines on hospital antibiotic use over a decade: a segmented time series analysis. PLoS ONE. 2014;9: e92206.","DOI":"10.1371\/journal.pone.0092206"},{"key":"525_CR23","doi-asserted-by":"crossref","unstructured":"Lambert M, Taxis K, Pont L. Impact of antibiotic shortages on antibiotic utilisation in the community. Pharmacoepidemiol Drug Saf. 2025;34: e70107.","DOI":"10.1002\/pds.70107"},{"key":"525_CR24","doi-asserted-by":"crossref","unstructured":"Gandra S, Takahashi S, Mitrani-Gold FS, Mulgirigama A, Ferrinho DA. A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems. JAC Antimicrob Resist. 2022;4: dlac125.","DOI":"10.1093\/jacamr\/dlac125"},{"key":"525_CR25","doi-asserted-by":"publisher","first-page":"e0054723","DOI":"10.1128\/aac.00547-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Bouvier M, Poirel L. Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to oral penems\/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and Taniborbactam \u03b2-lactamase inhibitors in Escherichia coli. Antimicrob Agents Chemother. 2023;67:e0054723.","journal-title":"Antimicrob Agents Chemother"},{"key":"525_CR26","doi-asserted-by":"publisher","first-page":"e2325212","DOI":"10.1001\/jamanetworkopen.2023.25212","volume":"6","author":"A Miyawaki","year":"2023","unstructured":"Miyawaki A, Kitajima K, Iwata A, Sato D, Tsugawa Y. Antibiotic prescription for outpatients with COVID-19 in primary care settings in Japan. JAMA Netw Open. 2023;6:e2325212.","journal-title":"JAMA Netw Open"},{"key":"525_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jiac.2023.02.015","volume":"29","author":"T Kato","year":"2023","unstructured":"Kato T, Nagasawa M, Tanaka I, Seyama Y, Sekikawa R, Yamada S. Single-center survey of prescription trends and appropriate use plans for macrolide antimicrobials. J Infect Chemother. 2023;29:599\u2013603.","journal-title":"J Infect Chemother"},{"key":"525_CR28","unstructured":"JAID\/JSC Infectious Diseases Treatment Guide and Guidelines Committee. The JAID\/JSC Guide to Clinical Management of Infectious Diseases 2023. The Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy. 2023. https:\/\/www.chemotherapy.or.jp\/modules\/basicauth\/index.php?file=JAIDJSC_Guide_2023. pdf. Accessed 13 Aug 2025."},{"key":"525_CR29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0954-6111(03)00042-8","volume":"97","author":"J Kadota","year":"2003","unstructured":"Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, Kohno S. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003;97:844\u201350.","journal-title":"Respir Med"},{"key":"525_CR30","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.resinv.2024.10.007","volume":"62","author":"SI Ohmura","year":"2024","unstructured":"Ohmura SI, Masui T, Yukishima T, Ohkubo Y, Yonezawa H, Miyamoto T. Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids. Respir Investig. 2024;62:1195\u2013201.","journal-title":"Respir Investig"},{"key":"525_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jiac.2016.03.001","volume":"22","author":"M Shibasaki","year":"2016","unstructured":"Shibasaki M, Komatsu M, Sueyoshi N, Maeda M, Uchida T, Yonezawa H, Inagaki K, Omi A, Matsumoto H, Murotani M, Iwamoto T, Kodaka Y, Kieda H, Tokiwa M, Masuwa B, Kinoshita M, Saito K, Katou M. Community spread of extended-spectrum \u03b2-lactamase-producing bacteria detected in social insurance hospitals throughout Japan. J Infect Chemother. 2016;22:395\u20139.","journal-title":"J Infect Chemother"},{"key":"525_CR32","first-page":"214","volume":"74","author":"MC O\u2019Grady","year":"2019","unstructured":"O\u2019Grady MC, Barry L, Corcoran GD, Hooton C, Sleator RD, Lucey B. Empirical treatment of urinary tract infections: how rational are our guidelines? J Antimicrob Chemother. 2019;74:214\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"525_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","volume":"56","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56:593\u2013619.","journal-title":"J Gastroenterol"},{"key":"525_CR34","doi-asserted-by":"publisher","first-page":"102511","DOI":"10.1016\/j.jiac.2024.08.025","volume":"31","author":"K Oda","year":"2025","unstructured":"Oda K, Okamoto S, Iwanaga E, Nakata H. Investigating the who\u2019s aware classification for assessing antimicrobial stewardship programs: A single-center study. J Infect Chemother. 2025;31:102511.","journal-title":"J Infect Chemother"},{"key":"525_CR35","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.ijantimicag.2005.08.001","volume":"26","author":"K Tamura","year":"2005","unstructured":"Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in japan: validation by the Japan febrile neutropenia study group. Int J Antimicrob Agents. 2005;26:S123\u201340.","journal-title":"Int J Antimicrob Agents"},{"key":"525_CR36","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1346-8138.14355","volume":"45","author":"N Hayashi","year":"2018","unstructured":"Hayashi N, Akamatsu H, Iwatsuki K, Shimada-Omori R, Kaminaka C, Kurokawa I, Kono T, Kobayashi M, Tanioka M, Furukawa F, Furumura M, Yamasaki O, Yamasaki K, Yamamoto Y, Miyachi Y, Kawashima M. Japanese dermatological association guidelines: guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018;45:898\u2013935.","journal-title":"J Dermatol"},{"key":"525_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/jdv.20391","volume":"39","author":"Z Apalla","year":"2025","unstructured":"Apalla Z, Freites-Martinez A, Grafanaki K, Ortiz-Brugues A, Nikolaou V, Fattore D, Sollena P, Deverapalli S, Babakoohi S, Galimont A, Kluger N, Beylot-Barry M, Larocca C, Iriarte C, Smith J, Tattersall I, Dodiuk-Gad R, Sauder M, Carrera C, Kwong B, Whitley M, Leboeuf N, Romano P, Starace M, Mateeva V, Riganti J, Hirner J, Patel AB, Reyes-Habito CM, Kraehenbuehl L, Kheterpal M, Fida M, Hassel J, Lacouture M, Sibaud V. Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe\/USA Delphi consensus process. J Eur Acad Dermatol Venereol. 2025;39:730\u201341.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00525-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:57:14Z","timestamp":1769518634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00525-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7514843\/v1","asserted-by":"object"}]},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Review Board of Kochi University School of Medicine (registration number: ERB-111871). All procedures adhered to the tenets of the Declaration of Helsinki. The requirement for informed consent was waived by the Ethical Review Board of Kochi University School of Medicine because of the retrospective, observational nature of the study. Moreover, only medical and related information was used to conduct the study, with no invasive or other intervention performed on the patients. Information on the conduct of the study was disclosed and patients were given the opportunity to refuse participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}